Abstracts tagged "CyTOF"

Abstract Number: 2734 • 2019 ACR/ARP Annual Meeting
Signaling Lymphocytic Activation Molecule Family (SLAMF) Receptors Deregulation Is Implicated in the Altered Function of NK Cells in Systemic Lupus Erythematosus
Morgane Humbel ¹, Florence Bellanger ¹, Craig Fenwick ², Alice Horisberger ³, Camillo Ribi ³ and Denis Comte¹, ¹Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Epalinges, Vaud, Switzerland, ²Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Epalinhes, Vaud, Switzerland, ³Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Vaud, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterized by quantitative and qualitative deficiencies of immune cells. Natural killer (NK) cells are innate…
Abstract Number: 99 • 2019 ACR/ARP Annual Meeting
Mass Cytometry Immunophenotyping of Synovial Fluid from Checkpoint Inhibitor Related Arthritis
Runci Wang¹, Karmela Kim Chan ², Amy Cunningham-Bussel ³, Laura Donlin ⁴, Gregory Vitone ², Aidan Tirpack ², Caroline Benson ², Gregory Keras ³, Anna Helena Jonsson ⁵, Michael Brenner ⁶, Anne Bass ⁷ and Deepak Rao ¹, ¹Brigham and women's hospital, Boston, MA, ²Hospital For Special Surgery, New York, ³Brigham and women's hospital, Boston, ⁴Hospital For Special Surgery, New York, NY, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women’s Hospital:, Boston, ⁷Hospital for Special Surgery/Weill Cornell Medicine, New York, NY
Background/Purpose: Anti-PD-1/PD-L1 checkpoint inhibitor therapies have produced remarkable results in stimulating immune responses against tumors. Checkpoint inhibitor therapy can also trigger a variety of autoimmune…
Abstract Number: 1033 • 2019 ACR/ARP Annual Meeting
Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus
Ye Cao¹, Stephen Alves ², Corine Sinnette ³, Cameron Speyer ³, Gregory Keras ¹, Yujie Qu ², Joshua Keegan ⁴, James Lederer ⁴, Deepak Rao ³ and Karen Costenbader ³, ¹Brigham and Women's Hospital, Boston, ²Merck, boston, ³Brigham and Women's Hospital, Boston, MA, ⁴BWH, Boston
Background/Purpose: The immune cell subsets most altered early in SLE disease course remain unclear. Defining abnormalities in lymphocyte populations in patients with new-onset SLE may…
Abstract Number: 135 • 2018 ACR/ARHP Annual Meeting
High Dimensional Analysis By Mass Cytometry and RNA-Sequencing Reveals Altered Frequency and Exhausted Features of CD4 T and MAIT Cells in Systemic Sclerosis
Bhairav Paleja¹, Andrea Hsiu Ling Low², Pavanish Kumar¹, Suzan Saidin¹, Ahmad Lajam², Camillus Chua³, Liyun Lai¹ and Salvatore Albani⁴, ¹Translational Immunology Institute, Singhealth/Duke-NUS Academic Medical Centre, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³Translational Immunology Institute, Singhealth/Duke-NUS Academic Medical Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ⁴Translational Immunology Institute, Singhealth/Duke-NUS Acedemic Medical Centre, Singapore, Singapore
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterised by excessive fibrosis of skin and internal organs, and vascular dysfunction. Association of T and B…
Abstract Number: 1104 • 2018 ACR/ARHP Annual Meeting
Mass Cytometry Analysis Detects Dysregulated T Cell Complement Responses in Diffuse Cutaneous Systemic Sclerosis
Giuseppina Arbore¹, Shahram Kordasti², Claudia Kemper^3,4,5, Dennis Hourcade⁶, Benedetta Costantini², Leo Placais³, Lynne Mitchell⁶, Richard Ellis⁴, Christopher P. Denton⁷, David Abraham⁸ and Voon H. Ong⁸, ¹Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy, ²Systems Cancer Immunology Lab, King's College London, London, United Kingdom, ³Laboratory of Molecular Immunology and the Immunology Center, National Institutes of Health, Washington, WA, ⁴School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁵Institute for Systemic Inflammation Research, University of Lübeck, Lübeck, Germany, ⁶Division of Rheumatology, Washington University School of Medicine, St Louis, WA, ⁷UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ⁸Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Aberrant CD4+ T cell activation is implicated in disease progression in systemic sclerosis (SSc). Activated T cells release various cytokines that may drive inflammation,…
Abstract Number: 1832 • 2018 ACR/ARHP Annual Meeting
Proteomic and Transcriptomic Profiling of Cells in Ankylosing Spondylitis Patients Identifies a Novel, Synovial-Resident CD8+ T Cell
Zoya Qaiyum¹, Eric Gracey², Yuchen Yao² and Robert D Inman³, ¹Department of Immunology, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada
Background/Purpose: Current data suggests that immune events in the gut may impact on joint inflammation in ankylosing spondylitis (AS) but what directs cells in the…
Abstract Number: 2029 • 2018 ACR/ARHP Annual Meeting
Extended Phenotypic Immunome Characterization (EPIC): A Web-Based Immune Reference Atlas
Joo Guan Yeo^1,2, Pan Lu¹, Thaschawee Arkachaisri^1,2, Su Li Poh¹, Fauziah Ally¹, Jing Yao Leong³, Kee Thai Yeo^1,2, Loshinidevi D/O Thana Bathi¹, Yun June Angela Tan², Seck Choon Elene Lee² and Salvatore Albani^1,4, ¹Translational Immunology Institute, Singhealth/Duke-NUS Academic Medical Centre, Singapore Health Services Pte Ltd, Singapore, Singapore, ²KK Women's and Children's Hospital, Singapore, Singapore, ³Translational Immunology Institute, Singhealth/Duke-NUS Academic Medical Centre, Singapore, Singapore, ⁴Translational Immunology Institute, Singhealth/Duke-NUS Acedemic Medical Centre, Singapore, Singapore
Background/Purpose: An atlas of the developing immune system will aid in our understanding of its normal maturation and identification of disease-associated cell subsets. The availability…
Abstract Number: 2837 • 2018 ACR/ARHP Annual Meeting
Diminished STAT-3 Phosphorylation and Associated Cell Pathways Characterize MMF-Treated Systemic Lupus Erythematosus Patients
Samantha Slight-Webb¹, Joel M. Guthridge¹, Eliza Chakravarty¹, Hua Chen¹, Rufei Lu², Krista M. Bean¹, Holden T. Maecker³, Paul J. Utz⁴ and Judith A. James⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Stanford University, Stanford, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Mycophenolate mofetil (MMF) is a commonly used medication to treat major organ involvement in SLE, specifically in patients with lupus nephritis. The safety and…
Abstract Number: 2903 • 2018 ACR/ARHP Annual Meeting
Single Cell Association Testing Identifies an Expanded Th1-Skewed Cytotoxic Effector CD4+ T Cell Subset in Rheumatoid Arthritis
Chamith Fonseka¹, Deepak Rao², Nikola Teslovich³, Ilya Korsunsky⁴, Susan Hannes⁵, Kamil Slowikowski¹, Michael Gurish⁶, Laura T. Donlin⁷, James A. Lederer⁸, Michael Weinblatt⁹, Elena Massarotti⁹, Jonathan Coblyn⁹, Simon Helfgott¹⁰, Derrick J. Todd¹¹, Vivian P. Bykerk¹², Elizabeth Karlson¹³, Joerg Ermann¹⁴, Yvonne C. Lee¹⁵, Michael Brenner¹⁶ and Soumya Raychaudhuri^1,17, ¹Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Human Immunology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Genetics and Rheumatology, Department of Medicine, Harvard Medical School, Boston, MA, ⁴Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Genetics, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁸Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, ¹¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹²Deptartment of Rheumatology, Hospital for Special Surgery, New York, NY, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ¹⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁶Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁷Program in Medical and Population Genetics, Broad Institute, Boston, MA
Background/Purpose: Defining the precise CD4+ T cell subsets that are dysregulated in RA patients is critical to deciphering pathogenesis. Here we present Mixed effects modeling…
Abstract Number: 2946 • 2018 ACR/ARHP Annual Meeting
T Peripheral Helper Cells Are Expanded in the Circulation of Active SLE Patients and Correlate with CD21low B Cells
Deepak Rao¹, Alexandra Bocharnikov², Chamith Fonseka³, Joshua Keegan², Betty Diamond⁴, Jennifer Anolik⁵, Peter Nigrovic¹, Soumya Raychaudhuri^3,6, James A. Lederer⁷ and Michael Brenner⁸, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Autoimmune Musculoskeletal and Hematopoietic Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute, Harvard University, Cambridge, MA, ⁷Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Pathologic T cell-B cell interactions and production of autoantibodies are hallmark features of SLE. T follicular helper (Tfh) cells are generally considered the principal…
Abstract Number: 2949 • 2018 ACR/ARHP Annual Meeting
African American and European American SLE Patients with Variable Disease Activity Reveal Distinct Differences in B Cells and TLR7/8 Pathways
Samantha Slight-Webb¹, Miles C. Smith¹, Holden T. Maecker², Paul J. Utz³, Joel M. Guthridge¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Stanford University, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disorder with a heterogeneous clinical presentation and periods of waxing and waning disease. Heterogeneity in SLE is…
Abstract Number: 1406 • 2017 ACR/ARHP Annual Meeting
Methods for Generating Multiple High-Dimensional Analyses of Cryopreserved Synovial Tissue Developed By the Accelerating Medicines Partnership RA/SLE Network
Deepak Rao¹, Laura T. Donlin², Kevin Wei³, Nida Meednu⁴, Jason Turner⁵, Mandy J. McGeachy⁶, Fumitaka Mizoguchi⁷, Joshua Keegan⁸, James Lederer⁹, Maria Gutierrez-Arcelus¹⁰, Kamil Slowikowski¹¹, Kaylin Muskat¹², Joshua Hillman¹², Cristina Rozo¹³, Edd Ricker¹⁴, Thomas Eisenhaure¹⁵, David Lieb¹⁵, Shuqiang Li¹⁵, Edward Browne¹⁵, Chad Nusbaum¹⁵, William H. Robinson¹⁶, Stephen Kelly¹⁷, Alessandra B. Pernis¹⁸, Lionel Ivashkiv¹⁹, Susan M. Goodman²⁰, Ellen M. Gravallese²¹, Michael Holers²², Nir Hacohen²³, Costantino Pitzalis¹⁷, Peter Gregersen²⁴, Vivian P. Bykerk²⁵, Larry W. Moreland²⁶, Gary Firestein²⁷, Soumya Raychaudhuri²⁸, Andrew Filer²⁹, David L. Boyle³⁰, Michael Brenner¹⁰ and Jennifer H. Anolik⁴, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ³Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Medicine, University of Pittsburgh, Pittsburgh, PA, ⁷Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁰Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical Schoo, Boston, MA, ¹²University of California, San Diego, San Diego, CA, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Weill Cornell Graduate School of Medical Sciences, New York, NY, ¹⁵Broad Institute, Cambridge, MA, ¹⁶Stanford University School of Medicine, Stanford, CA, ¹⁷Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ¹⁸David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ¹⁹Medicine, Hospital for Special Surgery, New York, NY, ²⁰Medicine, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²¹Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA, ²²Medicine, Division of Rheumatology, University of Colorado Denver, Aurora, CO, ²³Harvard Medical School, Boston, MA, ²⁴The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, ²⁵2-005, Mt Sinai Hospital, Toronto, ON, Canada, ²⁶Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²⁷EGG, St Cloud, France, ²⁸Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²⁹Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ³⁰University of California San Diego, La Jolla, CA
Background/Purpose: Detailed analyses of cells from rheumatoid arthritis (RA) synovium may identify cell phenotypes and functions that drive tissue pathology and joint damage. The AMP…
Abstract Number: 1577 • 2017 ACR/ARHP Annual Meeting
Deciphering the Role of the Tissue Microenvironment in Shaping the Immune Landscape in Psoriatic Arthritis
Jin Hui Sherlynn Chan¹, Ying Ying Leung², Warren Fong², Yi Wei Yeo², Bhairav Paleja¹, Liyun Lai¹, Suzan Saidin¹, Camillus Chua¹, Sharifah Nur Hazirah¹, Su Li Poh¹, Andrea Hsiu Ling Low² and Salvatore Albani^1,3, ¹SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: Psoriatic arthritis (PsA) occurs in a third of patients with psoriasis (Ps) and up to 30% of patients with PsA do not have an…
Abstract Number: 1736 • 2017 ACR/ARHP Annual Meeting
Deep Immunophenotyping of T-Lymphocytes with a 37-Channel Mass Cytometry (CyTOF) Panel for the Identification of Pathological Cell Functions and the Prediction of Response to Biologic Drugs in Rheumatoid Arthritis
Ben Mulhearn^1,2,3, Darren Plant², Ann W. Morgan^4,5, Anthony G. Wilson⁶, John D Isaacs^7,8, Jane Worthington⁹, Soumya Raychaudhuri^9,10,11,12, Tracy Hussell¹, Anne Barton^13,14 and Sebastien Viatte², ¹Manchester Collaborative Centre for Inflammation Research, University of Manchester, Manchester, United Kingdom, ²The University of Manchester, Arthritis Research UK Centre for Genetics and Genomics, , Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Medicine, Biology and Health, Manchester, United Kingdom, ³Kellgren Centre for Rheumatology, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁴Section of Musculoskeletal Disease, NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁶UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland, ⁷Institute of Cellular Medicine, Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁸National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ¹⁰Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute, Harvard University, Cambridge, MA, ¹²Partners Center for Personalized Genetic Medicine, Boston, MA, ¹³Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK, Manchester, United Kingdom, ¹⁴The Kellgren Centre for Rheumatology, Central Manchester Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Pathogenic immune cell types and functions have not been identified yet in rheumatoid arthritis (RA). This is explained by the impact of disease heterogeneity…
Abstract Number: 1941 • 2017 ACR/ARHP Annual Meeting
Microenvironmental and Systematic Evaluation of the Immunome in Osteoarthritis
Bhairav Paleja¹, Ying Ying Leung², Pavanish Kumar¹, Suzan Saidin¹, Ahmad Lajam², Liyun Lai¹ and Salvatore Albani¹, ¹SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore
Background/Purpose: Osteoarthritis is the most common joint disease and involves whole joint, including degeneration of articular cartilage and surrounding tissues. Although widely prevalent, the exact…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.